RECBIO
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project 2024-03-27 11:24
Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress 2024-03-21 00:22
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines 2023-12-29 12:33
Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair 2023-10-24 13:39
Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre 2023-10-10 13:54
Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress 2023-08-28 11:08
Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress 2023-07-27 10:57
Inclusion of Recbio In the MSCI China Small Cap Index 2023-05-17 14:01
Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia 2023-03-21 13:59
Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 2023-02-13 15:02
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine 2022-12-26 11:33
Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines 2022-12-19 13:53
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine 2022-12-14 15:17
Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine 2022-11-21 16:07
Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV 2022-11-08 15:17
Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine 2022-10-28 11:10
Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress 2022-08-29 13:08
Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines 2022-08-19 11:29
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine 2022-08-10 16:06
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines 2022-08-03 13:09
1 2